Delayed
Hong Kong S.E.
09:13:54 02/07/2024 am IST
|
5-day change
|
1st Jan Change
|
3.26
HKD
|
+0.31%
|
|
-3.55%
|
-10.68%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
5,209
|
1,990
|
2,149
|
1,960
|
-
|
-
|
Enterprise Value (EV)
1 |
2,718
|
-223.7
|
177.8
|
31.3
|
574.1
|
1,257
|
P/E ratio
|
-0.96
x
|
-3.54
x
|
-4.95
x
|
-3.69
x
|
-3.22
x
|
-3.12
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
230
x
|
-
|
113
x
|
7.78
x
|
7.03
x
|
7.18
x
|
EV / Revenue
|
120
x
|
-
|
9.33
x
|
0.12
x
|
2.06
x
|
4.61
x
|
EV / EBITDA
|
-8.6
x
|
0.46
x
|
-0.36
x
|
-0.65
x
|
-0.94
x
|
-1.82
x
|
EV / FCF
|
-15.2
x
|
0.62
x
|
-0.39
x
|
-0.18
x
|
-47.8
x
|
-3.89
x
|
FCF Yield
|
-6.58%
|
162%
|
-256%
|
-562%
|
-2.09%
|
-25.7%
|
Price to Book
|
2.05
x
|
0.75
x
|
1.08
x
|
1.09
x
|
1.72
x
|
3.29
x
|
Nbr of stocks (in thousands)
|
7,02,578
|
7,01,774
|
6,47,858
|
6,47,858
|
-
|
-
|
Reference price
2 |
7.415
|
2.835
|
3.318
|
3.025
|
3.025
|
3.025
|
Announcement Date
|
18/03/22
|
15/03/23
|
12/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
22.68
|
-
|
19.06
|
252
|
278.6
|
272.8
|
EBITDA
1 |
-316.2
|
-481.4
|
-492.7
|
-48.14
|
-608.6
|
-689.5
|
EBIT
1 |
-328.2
|
-497.2
|
-511.1
|
-54.67
|
-227.3
|
-543.2
|
Operating Margin
|
-1,447.05%
|
-
|
-2,681.41%
|
-21.69%
|
-81.56%
|
-199.16%
|
Earnings before Tax (EBT)
1 |
-1,810
|
-495.6
|
-431.6
|
-50
|
-
|
-
|
Net income
1 |
-1,810
|
-495.6
|
-431.6
|
-696.4
|
-914.6
|
-1,038
|
Net margin
|
-7,979.87%
|
-
|
-2,264.34%
|
-276.35%
|
-328.23%
|
-380.55%
|
EPS
2 |
-7.710
|
-0.8000
|
-0.6700
|
-0.8200
|
-0.9400
|
-0.9700
|
Free Cash Flow
1 |
-178.8
|
-363.5
|
-454.3
|
-176
|
-12
|
-323
|
FCF margin
|
-788.09%
|
-
|
-2,383.68%
|
-69.84%
|
-4.31%
|
-118.42%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
18/03/22
|
15/03/23
|
12/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022 Q2
|
2022 S1
|
2022 S2
|
2023 S1
|
2023 S2
|
2024 S1
|
2024 S2
|
---|
Net sales
1 |
-
|
-
|
-
|
19.06
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-223
|
-306.4
|
-390
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-0.3500
|
-0.3700
|
-0.4500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22/08/22
|
22/08/22
|
15/03/23
|
15/08/23
|
12/03/24
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
2,492
|
2,213
|
1,971
|
1,928
|
1,385
|
702
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-179
|
-364
|
-454
|
-176
|
-12
|
-323
|
ROE (net income / shareholders' equity)
|
-253%
|
-20.3%
|
-19.9%
|
-1.9%
|
-34.7%
|
-62.7%
|
ROA (Net income/ Total Assets)
|
-109%
|
-20.6%
|
-19.4%
|
-2.3%
|
-
|
-
|
Assets
1 |
1,660
|
2,402
|
2,225
|
30,278
|
-
|
-
|
Book Value Per Share
2 |
3.610
|
3.780
|
3.060
|
2.770
|
1.760
|
0.9200
|
Cash Flow per Share
2 |
-0.7200
|
-0.5500
|
-0.6900
|
-0.2400
|
-
|
-
|
Capex
1 |
9.01
|
19.6
|
12.3
|
25
|
25
|
25
|
Capex / Sales
|
39.74%
|
-
|
64.28%
|
9.92%
|
8.97%
|
9.17%
|
Announcement Date
|
18/03/22
|
15/03/23
|
12/03/24
|
-
|
-
|
-
|
Last Close Price
3.025
CNY Average target price
8.078
CNY Spread / Average Target +167.06% Consensus |
1st Jan change
|
Capi.
|
---|
| -10.68% | 270M | | +15.82% | 121B | | +20.35% | 113B | | +17.47% | 26.02B | | -25.31% | 19.39B | | -19.51% | 15.91B | | -19.67% | 15.09B | | -46.87% | 15.06B | | +62.55% | 14.93B | | +6.34% | 13.85B |
Bio Therapeutic Drugs
|